<DOC>
	<DOCNO>NCT02343614</DOCNO>
	<brief_summary>The treatment non-muscle invasive bladder cancer ( NMIBC ) problematic give variable natural history disease . Although contemporary treatment option limit , new target new approach investigation prevent bladder cancer recurrence progression . Among , COX-2 promising target since play important role urothelial carcinogenesis iCOX-2 selective inhibitor , like celecoxib , effectively inhibit tumor development growth enhances survival , bladder cancer vitro vivo model . Therefore , investigator conduct pilot study celecoxib prevent recurrence patient intermediate risk NMIBC .</brief_summary>
	<brief_title>Celecoxib Treatment Non-muscle Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Histologically proven urothelial bladder cancer Intermediate risk NMIBC ECOG Performance Status ≤ 2 Karnofsky Score ≥ 60 % Imaging study exclude upper urinary tract TCC Pregnant lactate woman ; Advanced coexist medical psychiatric disorder ; Positive history gastrointestinal disease ( peptic ulcer , inflammatory disease ) , intestinal bleeding ; History allergy sulfonamide drug ; Concomitant investigational medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Intermediate risk</keyword>
	<keyword>Cox-2 inhibitor</keyword>
</DOC>